secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALATIN TECHNOLOGIES INC (PTN)
CIK:        0000911216
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0001654954-23-012336
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palatin reports FY2023 net loss $27.5M; Vyleesi net revenue up 298%; PL9643 fully enrolled
--------------------------------------------------------------------------------

- Net loss of $27.5M ($2.53 diluted EPS) for FY2023 vs $36.2M loss ($3.79 EPS) in FY2022.
- Vyleesi net product revenue $4.9M in FY2023, up 298% YoY; Q4 net revenue $1.8M, up 128%.
- Phase 3 PL9643 (dry eye) fully enrolled (570 patients); topline data expected late Q4 2023.
- Phase 2 PL8177 (ulcerative colitis) interim analysis targeted Q1 2024; topline H1 2024.
- Cash $11.0M plus $2.9M receivables as of June 30; audit includes going concern paragraph.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/911216/000165495423012336/0001654954-23-012336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/911216/000165495423012336/ptn_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-012336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer